Mucosal healing is an independent predictor of sustained clinical remission in patients with ulcerative colitis (UC) treated with infliximab. We investigated whether infliximab concentrations during induction therapy are associated with short-term mucosal healing (STMH) in patients with UC.status: publishe
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously bee...
Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's dise...
Aim: To evaluate the effect of infliximab induction therapy on calprotectin levels in patients with ...
Mucosal healing is associated with favourable therapeutic outcomes in patients with ulcerative colit...
Infliximab (IFX) is a chimeric monoclonal antibody that neutralizes the pro-inflammatory cytokine tu...
International audienceBackgroundData on the value of therapeutic drug monitoring of infliximab (IFX)...
The trough concentration adapted infliximab treatment (TAXIT) trial demonstrated that maintaining in...
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation...
International audienceBACKGROUND:Mucosal healing can be achieved with infliximab (IFX).AIM:To assess...
Introduction: Infliximab (IFX) therapy intensification in ulcerative colitis (UC) is more common tha...
Background & AimsWe analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and A...
Background/Aims: Treatment of refractory ulcerative colitis (UC) is a clinical challenge, and after ...
Introduction. CT-P13 is the first biosimilar to infliximab that was approved for the same indication...
Objective Measuring of serum infliximab (IFX) induction concentrations might reduce primary non-resp...
Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease...
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously bee...
Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's dise...
Aim: To evaluate the effect of infliximab induction therapy on calprotectin levels in patients with ...
Mucosal healing is associated with favourable therapeutic outcomes in patients with ulcerative colit...
Infliximab (IFX) is a chimeric monoclonal antibody that neutralizes the pro-inflammatory cytokine tu...
International audienceBackgroundData on the value of therapeutic drug monitoring of infliximab (IFX)...
The trough concentration adapted infliximab treatment (TAXIT) trial demonstrated that maintaining in...
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation...
International audienceBACKGROUND:Mucosal healing can be achieved with infliximab (IFX).AIM:To assess...
Introduction: Infliximab (IFX) therapy intensification in ulcerative colitis (UC) is more common tha...
Background & AimsWe analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and A...
Background/Aims: Treatment of refractory ulcerative colitis (UC) is a clinical challenge, and after ...
Introduction. CT-P13 is the first biosimilar to infliximab that was approved for the same indication...
Objective Measuring of serum infliximab (IFX) induction concentrations might reduce primary non-resp...
Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease...
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously bee...
Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's dise...
Aim: To evaluate the effect of infliximab induction therapy on calprotectin levels in patients with ...